ARCADIA, Calif., Nov. 8 /PRNewswire/ -- The Health Resource Service Administration (HRSA) announced today that StemCyte, Inc. has been selected to help build a national inventory of 150,000 cord blood units under the C.W. Bill Young Cell Transplantation Program. The awards were the first such disbursement of the $79 million authorized by Congress in the Stem Cell Therapeutic and Research Act of 2005 and signed into law by President Bush. HRSA selected StemCyte as one of six cord blood banks in the country from a competitive proposal process. "StemCyte is delighted to have been chosen to help build our country's national cord blood inventory," says Ken Giacin, StemCyte's CEO. "We applaud the sponsors of the bill in Congress for their vision of building a resource for all Americans -- particularly those from under-represented communities -- and appreciate HRSA for making that vision a reality." StemCyte has one of the largest and most ethnically diverse cord blood banks, with 88% of its 26,000+ units coming from ethnic minorities. StemCyte is the largest donor bank within the National Marrow Donor Program network and has shipped nearly 400 units to leading transplant physicians around the world. Tens of thousands of Americans die each year from leukemia, lymphoma, sickle cell disease and other blood disorders because they cannot find a suitable match for a stem cell transplant. "Cord blood offers patients a safe, effective, and readily available source of stem cells to treat nearly 70 diseases and conditions," says Lawrence D. Petz, M.D., StemCyte's Chief Medical Officer, and Emeritus Professor of Pathology and Laboratory Medicine, UCLA Medical Center. "By increasing the national cord blood inventory by 150,000 units, StemCyte and the other banks selected will ensure a match for an estimated 90% of U.S. patients who need a transplant." StemCyte will continue to work with the other entities in the C. W. Bill Young Cell Transplantation Program, such as the National Marrow Donor Program, the Center for International Blood and Marrow Transplant Research (CIBMTR), and transplant centers to meet the needs of these patients. To find out more visit StemCyte online at www.stemcyte.com. About StemCyte, Inc. StemCyte, Inc., headquartered in Arcadia, California, intends to create the largest donor umbilical cord blood stem cell bank in the world. StemCyte is dedicated to providing high quality, cost-effective, stem cell transplantation and therapy to all patients in need. StemCyte is accredited by AABB, the College of American Pathologists (CAP), and the National Marrow Donor Program (NMDP). Additionally, the StemCyte International Cord Blood Center is accredited by the Foundation for Accreditation of Cellular Therapies (FACT) for cord blood collection, processing, testing, banking, selection and release. CONTACT: David Carmel StemCyte, Inc. 917-414-4121
SOURCE StemCyte, Inc.